Professional activity
since 2024
Infectologist, Hepatologist, Head of clinical service, "EUROLAB", Yerevan,
since 2022
Head of the Department of Infectious Diseases, National Institute of Health
since 2021
WHO focal point on Viral Hepatitis
since 2021
President of the Armenian Association of Infectious Diseases
2020-2023
Chairman of the ethics committee, "National Center of Infectious Diseases of the RA Ministry of Health" Armenia
2020-2023
Deputy Director (Development, Science), National Centre of Infectious Diseases
2020-2022
Head of Department of Infectious Diseases and Epidemiology, National Institute of HealthNational Institute of Health"
2020-2022
Global Fund Projects Coordinator in NCID, Armenia
since 2020
Scientific council Member, National Institute of Health
2019-2020
Assistant Professor: Department of Epidemiology, Microbiology and Infectious Diseases, "National Institute of Health"
since 2018
Infectologist, hepatologist in Elit-Med Medical Center
since 2018
Ministry of Health, Consultant in the field of Infectious Diseases
2016-2019
Hepatologist in Medecins sans frontiers (MSF) France in Armenia “HCV treatment with DAA among MDR-TB patients”
2007-2019
Infectologist, Department of Infectious Diseases, Armenicum Clinical Center
2007-2009
Head of the Department of Infectious Diseases, Yerevan State Medical University named after Mkhitar Heratsi
2007-2009
Scientific council Member, Yerevan State Medical Universit
2007-2009
Member of material and methods examination commission, Yerevan State Medical University
2004-2009
PhD research, topic – “Clinical, epidemiological peculiarities and results of treatment with Pegylated interferon-alpha 2a and Ribavirin of chronic viral hepatitis C in Armenia”, Yerevan State Medical University
1999-2007
Assistant Professor, Department of Infectious Diseases, Yerevan State Medical University
1998-2020
Infectologist in Nor-Arabkir Medical Center
Publications
177 (85 in English), include 23 in Russian and 104 in international publications, 60 abstracts and/or posters in international conference
EDITORIAL BOARD: «World Journal of Hepatology»
2023
Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study, The Lancet Gastroenterology & Hepatology, July 2023, DOI:https://doi.org/10.1016/S2468-1253(23)00197-8
2023
CURRENT ACHIEVEMENTS AND CHALLENGES IN VIRAL HEPATITIS B AND C ELIMINATION PROGRAM IN THE REPUBLIC OF ARMENIA, Global Hepatitis Summit 2023, P136, Paris, April 25-28
2023
Prevalence of anti-HBc seropositivity among checked patients in Armenia, 15th Paris Hepatology Conference, P 00009, 27-29 March, DOI:10.13140/RG.2.2.25810.43201
2023
CONNECTION OF HIV INFECTION EPIDEMICS IN THE REPUBLIC OF ARMENIA AND THE RUSSIAN FEDERATION, Epidemiol. infectious diseases. Current. question 2023; 13(3): 27–34, DOI:10.18565/epidem.2023.13.3.27–34
2023
The role of socio-demographic factors in the preference of behavioral strategies when seeking medical help in patients infected with HIV, Epidemiol. infectious diseases. Current. question 2023; 13(3): 35–42, DOI: https://dx.doi.org/10.18565/epidem.2023.13.3.35-42
2023
The necessity of antimicrobial stewardship program implementation and monitoring in Armenia, Armenian Journal of Health and Medical Sciences, 0231, p 66-67
2023
Changes in antiretroviral treatment approaches in the Republic of Armenia, Armenian Journal of Health and Medical Sciences, 0307, p. 67
2023
Features of the course and treatment of patients with coinfection TB/HIV and chronic hepatitis B and C, Armenian Journal of Health and Medical Sciences, p78-79
2023
ANALYSIS OF CASES OF VIROLOGICAL INEFFICIENCY OF ANTIRETROVIRAL THERAPY FOR HIV INFECTION AMONG RESIDENTS OF THE REPUBLIC OF ARMENIA, Molecular Diagnosticsand Biological Safety-2023, Сongress with international participation, Moscow, April, 27–28, p 208-209
2022
Acute severe hepatitis outbreak in children: A perfect storm. What do we know, and what questions remain? Frontiers in Pharmacology13:1062408, November. DOI: 10.3389/fphar.2022.1062408
2022
SITUATION WITH COVID-19 AMONG HIV-INFECTED PATIENTS IN ARMENIA, 20th Edition of the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paris, 8 Jun - 10 Jun, Poster 33, DOI: 10.13140/RG.2.2.14485.81122
2022
IMPLEMENTATION OF HCV-INFECTION TREATMENT PROGRAMM WITH DAA IN ARMENIA AMONG HIV-INFECTED PATIENTS IN COVID-19 ERA, 20th Edition of the European Meeting on HIV & Hepatitis - Treatment Strategies & Antiviral Drug Resistance, Paris, 8 Jun - 10 Jun, Poster 24, DOI:10.13140/RG.2.2.15691.67362
2022
Monkeypox A neglected infection becomes re-emerging global challenge. Armenian Journal of Health & Medical Sciences (AJHMS), September 2022 p.8-12, DOI: 10.54235/27382737-2022.v2.1-8
2022
Prevalence and risk factors of hepatitis C virus infection in Armenia, 2021, The European Journal of Public Health 32 (Supplement_3), October 2022 DOI: 10.1093/eurpub/ckac131.392
2022
Peculiarities of HIV infection in children in the Republic of Armenia. EECA INTERACT 2022 was held in Riga, Latvia, December 13-14, abstract 20, p.24-25
2022
Analyses of situation and implementation of new approach to PrEP in HIV-infected patients in Armenia. EECA INTERACT 2022 was held in Riga, Latvia, December 13-14, abstract 45, p.43-44 DOI: 10.13140/RG.2.2.14485.81122
2022
Prevalence of Pretreatment HIV-1 Drug Resistance in Armenia in 2017–2018 and 2020–2021 following a WHO Survey. Viruses 14(11):2320, October 2022 DOI: 10.3390/v14112320
2022
Integrating hepatitis C treatment into multidrug-resistant TB care, Public Health Action 12(2):96-101m June 2022 DOI: 10.5588/pha.22.0002
Scientific works
2021
Concomitant treatment of chronic hepatitis C with direct acting antivirals and multidrug-resistant tuberculosis is effective and safe, Open Forum Infectious Diseases, January 2021, DOI: 10.1093/ofid/ofaa653
2021
Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D, Endocrine 71(20). January 2021, DOI: 10.1007/s12020-020-02597-7
2020
Lipids profile, gamma-glutamyl transferase and hyperferritinemia in patients with NAFLD/NASH, 29th APASL Conference 2020, 4th-8th March, Bali, Nusa Dua
2020
PIVKA-II additional marker for HCC detection in HCV-infected patients after SVR in resource-limited setting, 29th APASL Conference 2020, 4th-8th March, Bali, Nusa Dua
2020
Vitamin D deficiency in patients with chronic liver diseases, 29th APASL Conference 2020, 4th-8th March, Bali, Nusa Dua
2020
Unusual combined case of liver cirrhosis due to HBV-infection and Budd-Chiari syndrome, 29th APASL Conference 2020, 4th-8th March, Bali, Nusa Dua
2020
Unusual case of severe herbs-induced systemic manifestations, 29th APASL Conference 2020, 4th-8th March, Bali, Nusa Dua
2019
HCC development in HCV-infected patients and diagnosis challenges in resource-limited settings, Poster Presentation №21, 17th International Workshop on Co-infection: HIV & Hepatitis, 22 - 24 May, Rome, Italy
2019
Influence of direct antiviral agents on fibrosis degree and outcome in patients with chronic hepatitis C, XXV Russian congress HEPATOLOGY TODAY, October 7-9, Moscow5
2019
Peculiarities of natural course of chronic hepatitis B, XXV Russian congress HEPATOLOGY TODAY, October 7-9, Moscow
2018
Hepatitis C and multidrug resistant tuberculosis co-morbidities: no longer an untreatable combination, Poster Presentation at Médecins Sans Frontières (MSF) Scientific Day, May 15, 2018, https://doi.org/10.7490/f1000research.1115465.1
2018
HYPERFERRITINEMIA IN PATIENTS WITH CHRONIC LIVER DISEASES, Poster Presentation (CC-04-099) abstract at the 27th Conference of the APASL, March 14th-18th, New Delhi, India
2018
DYNAMIC OF CLINICAL AND LABORATORY ABNORMALITIES IN SMALL COHORT OF HCV-INFECTED PATIENTS TREATED WITH SOFOSBUVIR CONTAIN REGIMENS, Poster Presentation (CC-04-059) abstract at the 27th Conference of the APASL, March 14th-18th, New Delhi, India
2018
CLINICAL AND VIROLOGICAL RESPONSE ON INDIAN GENERIC OF DAA REGIMENS WITH/WITHOUT IFN IN HCV-INFECTED PATIENTS, REAL WORLD DATA, Poster Presentation (CC-04-058) abstract at the 27th Conference of the APASL, March 14th-18th, New Delhi, India
2018
BIOCHEMICAL PARAMETERS ABNORMALITIES IN EBV-ASSOCIATED INFECTIOUS MONONUCLEOSIS, Poster Presentation (CC-01-051) abstract at the 27th Conference of the APASL, March 14th-18th, New Delhi, India
2018
Description of the Course and Outcomes of Antiviral Treatment of 1000 HCV Infected Patients, Poster Presentation, abstract at the 27th Conference of the APASL, March 14th-18th, New Delhi, India
2017
Real world data concerning rapid virological response and tolerability of DAAs with/without IFN regimens in small cohort of HCV-infected patients, 13th International Workshop on Co-infection: HIV & Hepatitis, on 21 - 23 June, Lisbon, Portugal
2017
Nosocomial outbreak of HCV-infection, Poster Presentation (PP1878) abstract SA-APASL2017-25497 at the 26th Conference of the APASL, Shanghai, China, 15th -19th February
2017
Result of short questionary concerning guidelines on management of HBV-infection among Armenian physicians, Poster Presentation (PP0791) abstract SA-APASL2017-25577 at the 26th Conference of the APASL, Shanghai, China, 15th -19th February
2017
Outcomes of Severe Complications in Patient with Decompensated HCV-associated Cirrhosis with SVR after Treatment with Sofosbuvir/Ledipasvir, Poster Presentation (PP1893) abstract SA-APASL2017-27938 at the 26th Conference of the APASL, Shanghai, China, 15th -19th February
2016
Success in difficult-to-treat patient with НСV-associated glomerulonephritis, Poster Presentation abstract 10110 at the 25th Conference of the APASL, Tokyo, Japan, February 20-24
2015
Influence of predictor variables on FibroMax results, Abstract/ePoster RS-2771 at the European Association for the Study of the Liver the 50th International Liver Congress (ILC), Vienna, Austria, April 22- 26, Hepatology, Vol.62, S 736-737
2015
Prognostic value of hyperferritinemia in patients with chronic hepatitis C, Poster Presentation POS-C4 at APASL STC on HCV, 18-20 December, New Delhi, India, Poster of Distinction
2015
Comparison of HCV genotyping distribution in Armenia during ten years, Abstract, Poster Presentation at the 22nd International Symposium on Hepatitis C Virus and Related Viruses meeting, Strasbourg, France, October 9-13
2014
Influence of predictor variables on degree of fibrosis in chronic НВV-infection measured by Fibrotest, Poster P73, EASL/APASL Special Conference on the Optimal Management of Hepatitis B Virus Infection in Athens, September 25-27
2013
INFLUENCE OF PREDICTOR VARIABLES ON QUALITY OF LIFE PATIENTS WITH CHRONIC VIRAL HEPATITIS C, Poster Presentation abstract A-533-0021-00223 at the 48th annual meeting of the European Association for the Study of the Liver, The Netherlands, April 24-28
2013
The experience of granulocyte colonystimulating factor administration for neutropenia correction in IFN-experienced patient with HCV-associated liver cirrhosis treated with Peg-IFN alpha 2a plus Ribavirin, Poster Presentation abstract A-535-0018-02382 at the 23rd Conference of the APASL, Singapore, 6-10 June
2013
Gammaglutamyltransferase in patient with chronic hepatitis C during the treatment with PEG Interferon Alfa 2a with ribavirin, 2nd Biannual Inter¬national Conference of Armenian Hepatological Forum, Yerevan September 6-7
2013
Results of IL-28B gene polymorphism in patients with chronic НCV-infection in Armenia, 2nd Biannual Inter¬national Conference of Armenian Hepatological Forum, Yerevan September 6-7
2013
Some results of GenoFibroTest in patients with chronic НСV-infection, 2nd Biannual Inter¬national Conference of Armenian Hepatological Forum, Yerevan September 6-7
2012
Immunoglobulins concentration in HIV-infected patients' with viral hepatitis, candidiasis and herpes simplex viral infection, International Symposium on HIV & Emerging Infectious Diseases, France, Marseille, 23-25 May Abstract-No:1215
2012
Predictor variables of efficacy the treatment with PEG Interferon Alfa 2a plus ribavirin in chronic hepatitis C, 14th International Symposium on Viral Hepatitis and liver Disease (ISVHLD), China, Shanghai 22-25 June
2011
Interrelationship of immune surrogate markers in HIV-infected patients, The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome 17-20 July, abstract CD-ROM, Abstract-No: A-361-0035-03722
2011
Immune surrogate markers in HIV-infected patients' with viral hepatitis, candidiasis and herpes simplex viral infection, The 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention in Rome 17-20 July, abstract CD-ROM, Abstract-No: A-361-0034-03805
2011
Biphasic thyroid dysfunction in patient with chronic hepatitis C treated with interferon-alpha and ribavirin, Poster Presentation abstract A-315-0024-01825 at the 21th Conference of the APASL, 17-20 February 2011, QSNCC, Bangkok Thailand
2011
Analysis of ferritinemia level in patients with chronic hepatitis C, 17th Russian Gastroenterology Weak, oral presentation
2010
Severe case of pneumocystis pneumonia in HIV-patient due to IRIS, Poster Presentation at 25th IUSTI Europe Conference
2010
Clinical aspects of chronic HCV-infection in Armenia, Poster Presentation at The 3rd International Tehran Hepatitis Congress
2010
Epidemiology of viral hepatitis C in Armenia, Poster Presentation at The 3rd International Tehran Hepatitis Congress
2010
Influence of predictor variables on side effects of the treatment with PEG interferon Alfa 2a plus ribavirin in chronic hepatitis C, Poster Presentation No.: P-144 at 4th Ditan International Conference on Infectious Diseases (DICID), International Journal of Infectious Diseases Abstract No. SA00360 (Prize Winner)
2010
Comparison of liver function tests in responders and non-responders of the treatment with PEG Interferon Alfa 2a plus ribavirin in chronic hepatitis C, Poster Presentation No.: PP-324 at the 20th Conference of the APASL, 25 – 28 March, Beijing, China
2008
Soluble Markers of Immune Activation in HIV/HCV Co-infection, 15th International Symposium on HIV & Emerging Infectious Diseases, France, Toulon, p. 2
2004-2009
Candidate thesis "Clinico-epidemiological and therapeutic features of chronic viral hepatitis C in Armenia"
